Q4 2018

Source filing unavailable

Q4 2018 · —

derived · Computed from the longer spans the company filed.

Revenue—

Net Income

-$8.86M

derivedno prior Q4 2017 on file

EPS, diluted—Not derived. Share counts vary by quarter.

Operating Cash Flowderived-$6,403,000—

Free Cash Flowderived-$9,869,000—

Same quarter

no prior Q4 2017 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fulcrum Therapeutics, Inc. · CIK 1680581 · Engraved from SEC EDGAR